Detalles de la búsqueda
1.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161271
2.
Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
Br J Cancer
; 129(1): 122-134, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37120672
3.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589218
4.
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry.
Breast Cancer Res Treat
; 197(2): 377-385, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417042
5.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988749
6.
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Breast Cancer Res
; 24(1): 80, 2022 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36401316
7.
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Br J Cancer
; 127(11): 1963-1973, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36207609
8.
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
BMC Cancer
; 22(1): 41, 2022 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34991520
9.
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Breast Cancer Res
; 23(1): 9, 2021 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33468209
10.
ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
Int J Cancer
; 149(1): 200-213, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33634878
11.
Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
Mod Pathol
; 34(7): 1282-1296, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33753865
12.
Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer.
Health Qual Life Outcomes
; 19(1): 56, 2021 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33579310
13.
Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/CT.
Eur J Nucl Med Mol Imaging
; 47(5): 1103-1115, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31396665
14.
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat
; 173(2): 397-406, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30357526
15.
SUV calculation in breast cancer: which normalization should be applied when using 18F-FDG PET?
Q J Nucl Med Mol Imaging
; 63(4): 399-407, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29345443
16.
Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.
Breast J
; 23(2): 138-145, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27935232
17.
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]. / La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques.
Ann Pathol
; 37(1): 133-141, 2017 Feb.
Artículo
en Francés
| MEDLINE | ID: mdl-28159406
18.
HER2-positive breast cancer: ¹8F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging
; 41(8): 1525-33, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24647576
19.
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Eur J Nucl Med Mol Imaging
; 41(3): 416-27, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24258007
20.
[Live birth rates after breast cancer among women who desired a child]. / Naissances vivantes après cancer du sein parmi les femmes désirant un enfant.
Bull Cancer
; 111(5): 463-472, 2024 May.
Artículo
en Francés
| MEDLINE | ID: mdl-38580527